Revvity (RVTY) Asset Writedowns and Impairment (2013 - 2023)

Revvity (RVTY) reported Asset Writedowns and Impairment of -$3.9 million for Q1 2023, down 148.73% quarter-over-quarter from $7.9 million in Q1 2021.

Revvity (RVTY) Asset Writedowns and Impairment (2013 - 2023) Analysis & Trends

Revvity has reported Asset Writedowns and Impairment for 3 years, with the latest figure at -$3.9 million in Q1 2023.

For the quarter ending Q1 2023, Asset Writedowns and Impairment changed N/A year-over-year to -$3.9 million; the trailing twelve-month figure through Dec 2023 stood at $4.3 million (changed N/A YoY), and the FY2025 full-year result was $4.8 million, down 79.03% from the prior year.
Asset Writedowns and Impairment for Q1 2023 stood at -$3.9 million, down from $7.9 million in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $7.9 million in Q1 2021, with the low at -$3.9 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Waters	30,010.71 Bn	30,010.25 Bn	1.11 Bn
2	Thermo Fisher Scientific	179.46 Bn	176.21 Bn	7.74 Bn
3	Danaher	130.33 Bn	124.64 Bn	3.59 Bn
4	Idexx Laboratories	44.44 Bn	44.24 Bn	722.74 Mn
5	Agilent Technologies	37.27 Bn	35.46 Bn	990.00 Mn
6	Iqvia Holdings	30.70 Bn	28.73 Bn	1.36 Bn
7	Natera	30.59 Bn	29.49 Bn	696.04 Mn
8	Illumina	24.86 Bn	23.71 Bn	721.00 Mn
9	Mettler Toledo International	23.06 Bn	23.00 Bn	555.82 Mn
10	Revvity	11.34 Bn	10.48 Bn	387.66 Mn

Download Data